Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

SUMMARY: Romosozumab, which binds sclerostin, rebuilds the skeletal foundation before transitioning to antiresorptive treatment. This subgroup analysis of an international, randomized, double-blind study in postmenopausal women with osteoporosis showed efficacy and safety outcomes for romosozumab fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arch Osteoporos
Main Authors: Miyauchi, Akimitsu, Dinavahi, Rajani V., Crittenden, Daria B., Yang, Wenjing, Maddox, Judy C., Hamaya, Etsuro, Nakamura, Yoichi, Libanati, Cesar, Grauer, Andreas, Shimauchi, Junichiro
Formato: Artigo
Idioma:Inglês
Publicado em: Springer London 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551345/
https://ncbi.nlm.nih.gov/pubmed/31168657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11657-019-0608-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados